EVO News and Press, Evotec SE From 04/24/24

2024-04-24 09:41:02 ET Summary Evotec SE's stock has declined over 30% in a single day, marking a 5-year decline of over 56%. The company's 2023A results met guidance, but the market expected more from the 2024E forecasts. The change in reporting structure and the stepping dow...

2024-04-24 08:45:23 ET More on pre-market losers & stocks. ING: Still Too Cheap Despite Disappointing Results ING Groep NV (ING) Q4 2023 Earnings Call Transcript Palisade Bio stock rallies nearly 100% on colitis drug analysis Palisade Bio stock slides 8% ...

2024-04-24 05:40:11 ET More on related stocks: Tesla: Q1 Wasn't Great, But The Growth Story Is Better Than Ever Tesla, Inc. (TSLA) Q1 2024 Earnings Call Transcript Evotec SE reports FY results; initiates FY24 outlook Tesla extends its gain after Elon Musk say...

2024-04-24 02:48:06 ET More on Evotec SE: Evotec and Variant Bio collaborate for fibrosis treatment Seeking Alpha’s Quant Rating on Evotec SE Historical earnings data for Evotec SE Financial information for Evotec SE Historical earnings data fo...

FINANCIAL RESULTS FOR 2023 FULLY MET UPDATED GUIDANCE PRIORITY RESET TO PROFITABLE GROWTH: SIZE & FOOTPRINT ADJUSTMENTS TO DRIVE EXPECTED ANNUALISED EBITDA IMPROVEMENT GREATER THAN € 40 M EVOTEC'S REPORTING STRUCTURE WILL CHANGE TO BUSINESS SEGMENTS “SHARED R&D&...

HAMBURG, GERMANY / ACCESSWIRE / April 23, 2024 / The Supervisory Board of Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) has appointed Dr Christian Wojczewski as the Company's new Chief Executive Officer ("CEO"), effective 01 July 2024. The election was un...

2024-04-18 08:25:02 ET More on Evotec SE Business Update Call Seeking Alpha’s Quant Rating on Evotec SE Historical earnings data for Evotec SE Financial information for Evotec SE Read the full article on Seeking Alpha For further detail...

COLLABORATION LEVERAGES VARIANT BIO'S CUTTING-EDGE GENOMIC DISCOVERY PLATFORM AND EVOTEC'S INTEGRATED END-TO-END R&D PLATFORM AND DISEASE AREA EXPERTISE TO ADDRESS UNMET MEDICAL NEED IN FIBROTIC INDICATIONS COMMERCIAL TERMS INCLUDE RESEARCH FUNDING AND MILESTONES AND/OR ROYALTY PAYMENTS ...

EVOTEC AND VARIANT BIO ENTER STRATEGIC PARTNERSHIP TO DISCOVER AND DEVELOP FIBROSIS TREATMENTS PR Newswire COLLABORATION LEVERAGES VARIANT BIO'S CUTTING-EDGE GENOMIC DISCOVERY PLATFORM AND EVOTEC'S INTEGRATED END-TO-END R&D PLATFORM AND DISEASE AREA EXPERTISE TO ADD...

HAMBURG, GERMANY / ACCESSWIRE / April 17, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for 2023 on Wednesday, 24 April 2024. The Company is going to hold a conference call to discuss the results as well as prov...